Adrian Mansini

Assistant Professor.
Cancer Research.
Prostate Cancer.
Melanoma.
Immuno-oncology.
Immunotherapy.

[Adrian Mansini @AdrianMansini]

B7-H6/NKp30 Axis in Melanoma: Translational Rationale, Evidence Gaps, and Therapeutic Considerations https://t.co/LqahvBOhJW

[Adrian Mansini @AdrianMansini]

Excited to share our latest work in Experimental Dermatology uncovering a keratinocyte–eosinophil inflammatory axis in bullous pemphigoid. The Secretome of Bullous Pemphigoid IgG-Treated Keratinocytes Induces a Pro-Inflammatory Eosinophil Response - PubMed https://t.co/n1RGuqKiSJ

[Adrian Mansini @AdrianMansini]

Our latest review on CD24 in melanoma is now available. #Melanoma #Immunotherapy. CD24 in Melanoma: Biomarker, Innate Immune Checkpoint and Emerging Therapeutic Target - PubMed https://t.co/dnEcRw80cQ

[Adrian Mansini @AdrianMansini]

Check out our latest review. #Melanoma #Immunotherapy #CancerResearch. Therapy-induced androgen receptor signaling as a candidate upstream driver of B7-H3-linked immune exclusion in melanoma: mechanisms and translational opportunities - PubMed https://t.co/FXnJsj0HFZ

[Adrian Mansini @AdrianMansini]

Our review “Sentinel Lymph Node Biopsy in Melanoma: Overview and Updates” is now out in IJMS. We discuss current practices, new techniques & the role of SLNB in the era of adjuvant therapy.
#Melanoma #SentinelLymphNode #Oncology #Dermatology #CancerResearch#RushUniversity

[Adrian Mansini @AdrianMansini]

Excited to share our new paper from the Department of Dermatology, Rush University Medical Center.
We highlight the role of androgen receptor (AR) in melanoma, its impact on immune evasion, and therapeutic opportunities. https://t.co/kkLa6i7InP

[Adrian Mansini @AdrianMansini]

@JochenReiser @gupta__vineet Congratulations!!!

[Gradilone Lab @GradiloneSergio]

Great visit and seminar today by @AdrianMansini - former postdoc in our lab- now PI at Rush University Medical Center @RushUniversity

[Adrian Mansini @AdrianMansini]

@yu_jindan @jdlicht @ArulChinnaiyan @SarkiAbdulkadi1 Congratulations, well deserved!!!

[Adrian Mansini @AdrianMansini]

https://t.co/8sT6ptVcPW

[Oncogene Journal @oncogenejournal]

MD2: a potential biomarker of #metastasis and #ProstateCancer progression to improve the outcome of the patients.
https://t.co/TXhj5QP5PX
@AdrianMansini

[Adrian Mansini @AdrianMansini]

I'm excited to share our recent article published in Oncogene!. We show the significance of MD2 in prostate cancer as a biomarker of metastasis and poor outcomes in patients. We also show MD2 as a therapeutic target.
https://t.co/ce4hBRFdrN

[Adrian Mansini @AdrianMansini]

https://t.co/fhzWrzAzHm

[Steve Kregel, PhD @SteveKregel]

Check out this highlight of some of our recent research efforts:
https://t.co/HCgZl43ArN
@LoyolaChicago @LoyolaUrology @AdrianMansini @RushUniversity @ChicagoITM @PCF_Science

[Adrian Mansini @AdrianMansini]

https://t.co/N5hjTI43qW

[Jay "Thymocyte" Hwang @Path4People]

Who knew blueberries could teach us about healthy cells? 🫐😲. Today’s #IntroToPath, I use 'em to explain metaplasia (🖤 blackberries), hyperplasia, and hypertrophy 💪🏽. It's like a berry-licious journey through the world of pathology! 🌎#Path4People #BerriesForEducation 🍓🍒🔬

[Adrian Mansini @AdrianMansini]

https://t.co/5UHHfLDAhw

[Adrian Mansini @AdrianMansini]

@HoeppnerLab Congratulations Luke!!!!!

[Direna Alonso-Curbelo @DirenaAC]

Come and join us to build #Innovation and lead the #Technology spearheading our Science at the @IRBBarcelona.

I recently joined the Institute and have been truly impressed by our excellent science #management colleagues that make impactful #research possible. ⚙️🔬🎯